The COVID-19 pandemic has seen the rapid development of a series of novel vaccines targeting SARS-CoV-2. Development of multiple COVID-19 vaccine candidates has been facilitated within Australia by the availability of high quality contract research organizations and a favorable regulatory environment. This webinar will provide an overview of strategies to conduct vaccine development within Australia.
The webinar will cover Australian research, regulatory and clinical infrastructure, which provides a favorable environment for rapid vaccine development. The webinar will also include discussion of a case study for rapid vaccine development based on non-clinical research conducted with a novel COVID-19 protein subunit vaccine. This case study will review key aspects of non-clinical design required to facilitate approval for first-in-human studies.
Dr. Brockman has gained considerable experience in the field of preclinical toxicology in his role at TetraQ during the past seven years. He currently designs and conducts preclinical rodent pharmacokinetic, toxicology and efficacy studies for external commercial entities, as well as collaborators within the University sector, for submission to regulatory authorities. He has lead projects as a postdoctoral researcher at the University of Minnesota in the US and at the University of Queensland in Australia ranging from determining the molecular mechanisms of treatments for chronic diseases to preclinical pharmacology and toxicology for drug discovery. Dr. Brockman has a strong interest in helping the biotech industry bring small molecules and biologics, particularly vaccines, through to clinical trials.
Dr. Tapley’s expertise is based on 28 years of experience in the biotechnology and pharmaceutical industry. His previous appointments include scientist and management roles at Ligand Pharmaceuticals and GlaxoSmithKline in the US. Prior to that he was a post-doctoral researcher at Bristol Myers Squibb and the Fred Hutchinson Cancer Research Centre. He also has 15 years experience in the rodent toxicology CRO sector which includes ‘hands on’ experience as a Study Director managing GLP studies and more recently as Test Facility Management at TetraQ. Dr. Tapley is motivated by his belief in drug discovery and development and brings that commitment to support the contract studies conducted at TetraQ.
Dr. Kurt Sales has over 20 years of experience in a career spanning research and development, research management, and business development in the UK and South Africa. At Agilex Biolabs, Kurt is responsible for management and oversight of the Agilex Biolabs Immunoassay division.
Kurt has extensive expertise in pre-clinical and clinical assay development, cellular and molecular biology, molecular signaling, flow cytometry, cell-based models, and biomarkers, notably in the areas of inflammation and immunology. He also has extensive experience ensuring strict GLP compliance for bioanalytical assays and preclinical safety testing through PK/PD/Biomarker assays.
Widely published with 45 peer-reviewed scientific papers in high impact journals, a book chapter and presentations at over 30 conferences, Kurt also received the prestigious Society for Reproduction and Fertility New Investigator Award.
Kurt has a Ph.D. in Medical Biochemistry, a Masters in Biochemistry, and a Bachelors of Science in Medicine with Honors in Pharmacology, and a Bachelor of Science in Biochemistry and Physiology. He has a Diploma in Business Organization and Management and a Post Graduate Certificate in Management.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.